The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis.
Autoimmunity
Multiple sclerosis
Semaphorins
T cells
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
02
03
2022
revised:
13
04
2022
accepted:
14
04
2022
pubmed:
24
4
2022
medline:
18
5
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
Immune semaphorins are widely accepted to have functional impact on autoimmune diseases. To assess the status of sema3A and sema4A in the pathogenesis of Multiple Sclerosis (MS). Sema3A expression on (T regulatory cells)Tregs was decreased in MS patients, compared to healthy controls (35.85 ± 16.7% vs 88.27 ± 3.8%; p ≤ 0.001). Serum levels of sema3A were decreased in MS patients 2.95 ± 0.43 vs 18.67 ± 5.7 ng/ml in healthy individuals; p ≤ 0.001. Sema4A serum levels were increased in MS patients compared to healthy individuals (12.99 ± 8.6 vs 5.83 ± 3.91 ng/ml; p ≤ 0.001). Sema3A and sema4A serum levels were found to be in negative/positive correlation with MS disease severity (r We show that sema3A is a regulatory molecule in MS, whereas sema4A is a stimulatory one. Targeting sema3A and sema4A could become a potential therapeutic approach in MS.
Sections du résumé
BACKGROUND
Immune semaphorins are widely accepted to have functional impact on autoimmune diseases.
OBJECTIVES
To assess the status of sema3A and sema4A in the pathogenesis of Multiple Sclerosis (MS).
RESULTS
Sema3A expression on (T regulatory cells)Tregs was decreased in MS patients, compared to healthy controls (35.85 ± 16.7% vs 88.27 ± 3.8%; p ≤ 0.001). Serum levels of sema3A were decreased in MS patients 2.95 ± 0.43 vs 18.67 ± 5.7 ng/ml in healthy individuals; p ≤ 0.001. Sema4A serum levels were increased in MS patients compared to healthy individuals (12.99 ± 8.6 vs 5.83 ± 3.91 ng/ml; p ≤ 0.001). Sema3A and sema4A serum levels were found to be in negative/positive correlation with MS disease severity (r
CONCLUSION
We show that sema3A is a regulatory molecule in MS, whereas sema4A is a stimulatory one. Targeting sema3A and sema4A could become a potential therapeutic approach in MS.
Identifiants
pubmed: 35460904
pii: S1521-6616(22)00098-5
doi: 10.1016/j.clim.2022.109017
pii:
doi:
Substances chimiques
SEMA3A protein, human
0
SEMA4A protein, human
0
Semaphorin-3A
0
Semaphorins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109017Informations de copyright
Copyright © 2022. Published by Elsevier Inc.